Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pravastatin Sodium

Known as: Pravastatin Sodium Salt, Pravastatin Sodium [Chemical/Ingredient], Sodium Salt, Pravastatin 
The sodium salt of pravastatin with cholesterol-lowering and potential antineoplastic activities. Pravastatin competitively inhibits hepatic… Expand
National Institutes of Health

Related topics

Related topics

15 relations

Narrower (4)

CS-514PravacholRMS-431SQ-31000
Coronary Artery DiseaseDrug AllergyHepatic Metabolism [PK]Hypercholesterolemia
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Buccal Drug Delivery of Pravastatin Sodium
The purpose of this study was to develop and optimize formulations of mucoadhesive bilayered buccal tablets of pravastatin sodium… Expand
  • table I
  • table II
  • table III
  • figure 1
  • table IV
Highly Cited
1999
Highly Cited
1999
Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.
OBJECTIVES We tested the hypothesis that pravastatin (PRA) activates endothelial nitric oxide synthase (eNOS). BACKGROUND… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
1998
Review
1998
Communicating the risk reduction achieved by cholesterol reducing drugs
“When the facts change, I change my mind. What do you do?” asked Professor Michael Oliver at a presentation held in Stockholm on… Expand
Highly Cited
1997
Highly Cited
1997
A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
OBJECTIVES To evaluate and compare the lipid-altering effects of conjugated estrogens and pravastatin, alone and in combination… Expand
Highly Cited
1996
Highly Cited
1996
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Elevated plasma fibrinogen level is known to progress atherosclerosis and to be one of the risk factors for the occurrence of… Expand
Highly Cited
1996
Highly Cited
1996
Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes…
It has been shown previously that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA RIs) such as compactin and… Expand
Highly Cited
1995
Highly Cited
1995
Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.
We examined whether serum cholesterol reduction alters the lesional composition of atherosclerotic plaques. To reduce serum… Expand
Highly Cited
1991
Highly Cited
1991
Biotransformation of pravastatin sodium in humans.
Pravastatin sodium (PV) is a potent cholesterol-lowering agent that acts by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A… Expand
Highly Cited
1990
Highly Cited
1990
Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.
Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two… Expand
Highly Cited
1990
Highly Cited
1990
Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Tissue selectivity of pravastatin sodium (pravastatin) in inhibition of cholesterol synthesis was investigated and its effect was… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE